<DOC>
	<DOC>NCT00720798</DOC>
	<brief_summary>This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 [Roche protocol WA18062], NCT00106574 [Roche protocol WA18063], and NCT00109408 [Roche protocol WA17824]) of adults with rheumatoid arthritis. Participants received tocilizumab alone or in combination with standard anti-rheumatic treatment.</brief_summary>
	<brief_title>An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>Patients who have completed participation in 1 of the core studies in adult rheumatoid arthritis. Treatment with any investigational agent since the last administration of study drug in the core studies. Treatment with iv gamma globulin, plasmapheresis, or prosorba column since the last administration of study drug in the core studies. Treatment with an antiTNF or antiIL1 agent, a Tcell costimulation modulator, or any biologic since the last administration of study drug in the core studies. Immunization with a live/attenuated vaccine since the last administration of study drug in the core studies. Previous treatment with any celldepleting therapies, including investigational agents. Parenteral, intramuscular, or intraarticular corticosteroids within 6 weeks prior to baseline in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>